ArticleFrontiers in medicine2026
Clinical efficacy of immunoglobulin in pediatric patients with severe respiratory syncytial virus pneumonia: a retrospective clinical analysis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The effectiveness of intravenous immunoglobulin (IVIG) in the treatment of severe respiratory syncytial virus pneumonia (SRSVP) remains a topic of ongoing debate. This study aimed to evaluate the association of IVIG on the duration of hospitalization and the use of corticosteroids in pediatric cases of SRSVP. Methods: To minimize confounding by indication, a 1:1 propensity score matching (PSM) was performed with a caliper width of 0.02. Multivariate logistic regression analysis was conducted for the entire cohort ( Results: Results showed that intravenous immunoglobulin (IVIG) treatment failed to reduce the duration of corticosteroid use, corticosteroid dosage, or length of hospital stay (OR = 4.634; OR = 4.667; OR = 2.566). Propensity score matching (PSM) successfully generated 41 well-balanced pairs. In the GEE/GZLM analysis (which further corrected for residual baseline imbalances in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatinine), IVIG treatment still failed to reduce the duration of glucocorticoid use (OR = 3.229, 95% CI: 1.267-8.232), reduce glucocorticoid dosage (OR = 2.653, 95% CI: 1.063-6.619), or shorten the length of hospital stay (OR = 4.375, 95% CI: 1.581-12.108). Furthermore, subgroup analysis showed that in infants <6 months of age, IVIG treatment did not shorten hospital stay and was not associated with glucocorticoid use outcomes. Conclusion: In conclusion, intravenous immunoglobulin (IVIG) treatment did not shorten hospital stays or reduce the use of glucocorticoids in children with severe respiratory syncytial virus pneumonia (SRSVP). Therefore, it is necessary to reassess the value of IVIG in the treatment of SRSVP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.